ArticleAmerican journal of cancer research2017
Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation.Frontiers in immunology · 2025Pooled it
- Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks.Frontiers in pharmacology · 2025Pooled it
- Pooled it
- Stress Biology in Cancer: Neuroendocrine-Immune Mechanisms Linking Tumor Progression to Translational Interventions.Cancer communications (London, England) · 2026Review
- The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Effect of antihypertensive drugs on survival in patients with non-small cell lung cancer on epidermal growth factor receptor inhibitors.American journal of cancer research · 2025Article
- Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies.Lung cancer management · 2023Article
- Article
- ß-Adrenoreceptors in Human Cancers.International journal of molecular sciences · 2023Review
- Chronic stress in solid tumor development: from mechanisms to interventions.Journal of biomedical science · 2023Review
- A lung cancer risk prediction model for nonsmokers: A retrospective analysis of lung nodule cohorts in China.Journal of clinical laboratory analysis · 2022Article
- Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.Frontiers in immunology · 2021Review
- β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators.Cancer medicine · 2020Article
- Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.PeerJ · 2019Article
- Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is known that hypertension could increase the plasma levels of VEGF and that β-blockers propranolol could counteract the effect. Our aim was to explore the possibility of improving survival outcomes for patients with and patients without hypertension. In addition, we also compared the efficacy of the usage of β-blockers in inoperable non-small cell lung cancer (NSCLC) patients. We retrospectively reviewed 1753 NSCLC patients who underwent concurrence/sequential chemoradiotherapy in our hospital from 1994 to 2005. A total of 606 inoperable patients with stage III were enrolled in this study. Fifty-five patients survived until the follow-up date of May 2011. From the 606 patients, 123 of them had hypertension. We identified 11 of them who took β-blockers orally. Kaplan-Meier methods and Cox proportional hazard model were utilized to analyze the overall survival (OS) outcome among patients with hypertension and patients without hypertension. After that, we compared the patients who took β-blockers with patients who did not take β-blockers in the whole stage III cohort using the same approaches. The Kaplan-Meier analysis revealed that there were no significant survival outcomes between hypertension and non-hypertention groups (P>0.05). No significant difference was found between using β-blockers and not using them in the hypertention group (P>0.05). We also found no statistical significance between using β-blockers and not using them in the whole cohort of 606 NSCLC patients (P>0.05). The results from both univariate or multivariate analysis using the Cox proportional hazards regression model indicated that there was no statistical difference between hypertension and non-hypertension group. There was also no difference between using β-blockers and not using them in the whole stage III cohort (P>0.05). For the patients with hypertension, the usage of β-blockers did not influence the overall survival in stage III inoperable NSCLC. Further randomized clinical trials will be warranted to validate this finding.
Indexed as
Identifiers
28469966PMC5411801W2697344394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.